GammaPod Registry and Quality of Life Nomogram
Tumor Bed Boost Using a Breast Specific Radiosurgery Device, The GammaPodTM: Registry Study and Evaluation of Quality of Life With Development of Sizing Nomogram
Who can join
As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.
- Age
- 18 Years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Compensation
- Not stated
Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.
What to expect
No one can promise a trial will help you personally — that is what the research is trying to find out.
What participation involves
Not stated in the study description — ask the study team about visits and procedures.
- Compensation
- Not stated
- Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
- Participants are monitored closely by the research team throughout the study.
- Some participants may receive access to an investigational treatment, which is still being studied.
- Your participation helps researchers learn whether this approach could help future patients.
About this study
This study is a prospective, single arm study (registry) summarizing patient-level adverse-event and tumor outcomes as well as a number of feasibility and dosimetric characteristics of delivering a single-fraction boost with the GammaPod.
Compensation is read from the study's own description and may be missing — always confirm with the study team.
Eligibility
Official eligibility criteria
Inclusion Criteria: * The patient must sign consent for study participation. * The patient must be female and have a diagnosis of an invasive or non-invasive breast cancer that was treated surgically by a partial mastectomy. * The patient must be deemed an appropriate candidate for breast conserving therapy (i.e. not pregnant, never had radiation to the treated breast, breast size would allow adequate cosmesis after volume loss from partial mastectomy). * Patients with involved lymph nodes are candidates for the study. * Surgical margins are negative for invasive (no tumor on ink) or non-invasive breast cancer (2 mm negative margin). * The greatest dimension of the tumor is less than 4cm before surgery. * Multifocal disease is allowed if it was removed by a single lumpectomy resection and the patient remained a candidate for breast conservation. * Age 18 years and older. * Women of childbearing potential (pre-menopausal defined as having a menstrual period within the past 1 year) must have a negative serum pregnancy test or complete a pregnancy waiver form per institutional policy. * The surgical cavity is clearly visible on CT images. Of note, clips are not required but recommended. * The patient must weigh less than 150Kg (330lb), which is the limit of the imaging couch. * The patient must be less than 6'6" in height. * The patient must feel comfortable in the prone position. * Diagnosis of prior contralateral breast cancer is allowed. * Diagnosis of synchronous bilateral cancers is allowed. In this case if bilateral boosts are required, a patient would not have both treatments on the same day. * Oncoplastic reduction surgery is allowed if the lumpectomy cavity can be clearly visualized. Exclusion Criteria: * Patients with proven multi-centric carcinoma (tumors in different quadrants of the breast or tumor separated by at least 4 cm). * Prior radiation therapy to that breast or that hemi thorax. * Unable to fit into the immobilization breast cup with an adequate seal. * Male gender. * Patient cannot comfortably be set up in the prone position (i.e. physical disability) * Unable to fit into the breast immobilization device due to breast size or other anatomical reason. * Mastectomy is the surgery performed. * Patient has received prior radiotherapy to the involved breast. * Tumor bed is less than 3 mm from the skin surface. * Greater than 50% of the target volume is above the upper border of the table. * Patients with skin involvement, regardless of tumor size. * Patients with connective tissue disorders specifically systemic lupus erythematosis, scleroderma, or dermatomyositis. * Patients with psychiatric or addictive disorders that would preclude obtaining informed consent. * Patients who are pregnant or lactating due to potential exposure of the fetus to RT and unknown effects of RT to lactating females. * Patients with breast implants/tissue expanders or flap reconstruction.
Study sites (4)
MD
- Upper Chesapeake Health · Bel Air, MD 21014Linda Romar, BS · Study contact · 443-643-1877 · lromar@umm.eduJack Hong, MD · Sub-investigatorMore trials in Bel Air
- Central Maryland Oncology Center · Columbia, MD 21044Madiha Qutab, M.S. · Study contact · 443-328-6472 · madiha.qutab@umm.eduSally Cheston, MD · Sub-investigatorMore trials in Columbia
- Baltimore Washington Medical Center · Glen Burnie, MD 21061Pilar Strycula, RN, BSN · Study contact · 410-553-8110 · Pstrycula@.umm.eduWendla Citron, MD · Sub-investigatorMore trials in Glen Burnie
TX
- UTSouthwestern · Dallas, TX 75390Sara Gamal · Study contact · 214-645-8519 · Sara.Gamal@UTSouthwestern.eduAsal Rahimi, MD, MS · Principal investigatorMore trials in Dallas